✦ LIBER ✦

ChemInform Abstract: KP1019, A New Redox-Active Anticancer Agent — Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

✍ Scribed by Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Groessl; Alexander Egger; Walter Berger; Haralabos Zorbas; Paul J. Dyson; Bernhard K. Keppler

Publisher: John Wiley and Sons
Year: 2009
Weight: 16 KB
Volume: 40
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200903241

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

📜 SIMILAR VOLUMES

KP1019, A New Redox-Active Anticancer Ag

KP1019, A New Redox-Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

✍ Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Gr 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 1 views

## Abstract The promising drug candidate indazolium __trans__‐[tetrachlorobis(1__H__‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (__Hartinger et al., J. Inorg. Biochem.__ **2006**, __100_